Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies
暂无分享,去创建一个
C. Lavie | A. Arbab-Zadeh | O. Sochor | Abhishek Sharma | J. Garg | P. Krishnamoorthy | E. Lichstein | Saurabh Thakar | Jalaj Garg
[1] P. Trouillas,et al. Intracerebral haematoma after application of nicotine patch , 1995, The Lancet.
[2] P. Hjemdahl,et al. Acute effects of low dose nicotine gum on platelet function in non-smoking hypertensive and normotensive men , 2004, European Journal of Clinical Pharmacology.
[3] N. Benowitz,et al. Dose‐related cardiovascular and endocrine effects of transdermal nicotine , 1998, Clinical pharmacology and therapeutics.
[4] Office on Smoking. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General , 2010 .
[5] W. Little,et al. Myocardial infarction in a patient who smoked while wearing a nicotine patch. , 1994, Annals of internal medicine.
[6] M. Verani,et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. , 1997, Journal of the American College of Cardiology.
[7] K. Wilson,et al. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals , 2010, Tobacco induced diseases.
[8] Jacob Abelson,et al. Reviews , 1974 .
[9] Dan Tzivoni,et al. Cardiovascular Safety of Transdermal Nicotine Patches in Patients with Coronary Artery Disease who Try to Quit Smoking , 1998, Cardiovascular Drugs and Therapy.
[10] D. Faulds,et al. Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. , 1992, Drugs.
[11] J. Ottervanger,et al. Acute myocardial infarction while using the nicotine patch. , 1995, Chest.
[12] S. Glantz,et al. Effective tobacco control is key to rapid progress in reduction of non-communicable diseases , 2012, The Lancet.
[13] H. McRobbie,et al. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis , 2013, Thorax.
[14] K. Perkins. Smoking Cessation in Women , 2001, CNS drugs.
[15] D. Singer,et al. Bupropion for smokers hospitalized with acute cardiovascular disease. , 2006, The American journal of medicine.
[16] M. Fiore,et al. The Effectiveness of the Nicotine Patch for Smoking Cessation , 1994 .
[17] J. Issa,et al. Effectiveness of sustained-release bupropion in the treatment of smoker patients with cardiovascular disease. , 2007, Arquivos brasileiros de cardiologia.
[18] Qi Zhang,et al. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. , 1993, Journal of the American College of Cardiology.
[19] N. Rigotti,et al. Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial , 2010, Circulation.
[20] S. Roose. Considerations for the use of antidepressants in patients with cardiovascular disease. , 2000, American heart journal.
[21] J. McNeil,et al. Predictors and Timing of Adverse Experiences During Transdermal Nicotine Therapy , 1999, Drug safety.
[22] Jonathan A. Zlabek,et al. Nicotine replacement therapy and cardiovascular disease. , 2005, Mayo Clinic proceedings.
[23] J. Issa,et al. Efetividade da Bupropiona no Tratamento de Pacientes Tabagistas com Doença Cardiovascular Effectiveness of Sustained-Release Bupropion in the Treatment of Smoker Patients with Cardiovascular Disease , 2007 .
[24] J. Prochaska,et al. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.
[25] Richard Platt,et al. Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. , 2013, JAMA internal medicine.
[26] B. Stricker,et al. Vasculitis attributed to the nicotine patch (Nicotinell) , 1996, The British journal of dermatology.
[27] R. J. Mather,et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid , 2007, Neuropharmacology.
[28] Selma Ari,et al. The effect of varenicline on heart rate variability in healthy smokers and nonsmokers , 2011, Autonomic Neuroscience.
[29] A. Blann,et al. The Influence of Smoking and of Oral and Transdermal Nicotine on Blood Pressure, and Haematology and Coagulation Indices , 1997, Thrombosis and Haemostasis.
[30] N. Herity,et al. Acute myocardial infarction soon after nicotine replacement therapy. , 2001, QJM : monthly journal of the Association of Physicians.
[31] L. Hillis,et al. Intranasal nicotine spray does not augment the adverse effects of cigarette smoking on myocardial oxygen demand or coronary arterial dimensions. , 1996, The American journal of medicine.
[32] H. Svanström,et al. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study , 2012, BMJ : British Medical Journal.
[33] J. Pierce. Stroke following Application of a Nicotine Patch , 1994, The Annals of pharmacotherapy.
[34] K. Haustein,et al. Comparison of the effects of combined nicotine replacement therapy vs. cigarette smoking in males. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[35] S. Kimmel,et al. Risk of acute first myocardial infarction and use of nicotine patches in a general population. , 2001, Journal of the American College of Cardiology.
[36] Xin Wang,et al. Endogenous acetylcholine and nicotine activation enhances GABAergic and glycinergic inputs to cardiac vagal neurons. , 2003, Journal of neurophysiology.
[37] B. Steele,et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. , 1996, The New England journal of medicine.
[38] Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. , 1994, Archives of internal medicine.
[39] R. Ritz,et al. Influence of moderately elevated levels of carboxyhemoglobin on the course of acute ischemic heart disease. , 1985, Respiration; international review of thoracic diseases.
[40] S. Greenland,et al. A Meta-Analysis to Assess the Incidence of Adverse Effects Associated with the Transdermal Nicotine Patch , 1998, Drug safety.
[41] N. Benowitz. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. , 2003, Progress in cardiovascular diseases.
[42] R. Hurst,et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. , 2007, Neuropharmacology.
[43] A. Sanfilippo,et al. Aortic dissection and use of the nicotine patch: a case involving a temporal relationship. , 1997, The Canadian journal of cardiology.
[44] R. Gonthier,et al. Myocardial infarction and nicotine patch: a contributing or causative factor? , 1993, European heart journal.
[45] L. Stead,et al. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. , 2014, Addiction.
[46] D. Cook,et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. , 2000, Archives of internal medicine.
[47] R. Perera,et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. , 2013, The Cochrane database of systematic reviews.
[48] Dependence Update Panel,et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. , 2008, American journal of preventive medicine.
[49] A. Nitenberg,et al. Effects of nicotine gum on coronary vasomotor responses during sympathetic stimulation in patients with coronary artery stenosis. , 1999, Journal of cardiovascular pharmacology.
[50] M. Beyens,et al. Serious Adverse Reactions of Bupropion for Smoking Cessation , 2008, Drug safety.
[51] A. Malliani,et al. Autonomic effects of nicotine patch administration in habitual cigarette smokers: a double-blind, placebo-controlled study using spectral analysis of RR interval and systolic arterial pressure variabilities. , 1998, Journal of cardiovascular pharmacology.
[52] B. Walsh,et al. Cardiovascular effects of bupropion in depressed patients with heart disease. , 1991, The American journal of psychiatry.
[53] C. Furberg,et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis , 2011, Canadian Medical Association Journal.
[54] Timothy B. Baker,et al. The Effectiveness of the Nicotine Patch for Smoking Cessation. A Meta-analysis , 1995 .
[55] Patricia Dolan Mullen,et al. Treating tobacco use and dependence: clinical practice guideline , 2000 .
[56] Kristian Thorlund,et al. Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies: A Network Meta-Analysis , 2014, Circulation.
[57] T. Payne,et al. Treating nicotine dependence. , 2003, The American journal of the medical sciences.
[58] S. Tonstad,et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. , 2003, European heart journal.
[59] M. Harrison‐Woolrych,et al. Cardiovascular Events in Patients taking Varenicline , 2012, Drug Safety.
[60] Tim Lancaster,et al. Nicotine receptor partial agonists for smoking cessation. , 2010, The Cochrane database of systematic reviews.